SCHEMBL4773230

SCHEMBL4773230

CC(=O)C(c1ccc(Cl)c(Cl)c1)N1CCC(c2cccc(-c3ccccc3)c2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 1/20 0.41
SLC6A4 P31645 1/20 0.41
SLC6A3 Q01959 1/20 0.41
HRH1 P35367 4/20 0.40
CCR3 P51677 4/20 0.40
KCNH2 Q12809 3/20 0.40
SLC18A3 Q16572 2/20 0.40
SIGMAR1 Q99720 1/20 0.40
EGFR P00533 1/20 0.40
LMNA P02545 1/20 0.40
TP53 P04637 1/20 0.40
MAPT P10636 1/20 0.40
MCHR1 Q99705 2/20 0.39
OPRM1 P35372 2/20 0.39
HSD17B2 P37059 1/20 0.39
CNR1 P21554 1/20 0.38
CNR2 P34972 1/20 0.38
DRD2 P14416 1/20 0.38
ADRA1A P35348 1/20 0.38
CYP1A2 P05177 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12175058 0.76 KCNH2 (0.52) KCNH2SLC18A3LMNAOPRM1MEN1
SCHEMBL890109 0.76 KCNH2 (0.52) KCNH2SLC18A3LMNAOPRM1MEN1
SCHEMBL4778510 0.72 AKT1 (0.50) LMNATP53MAPT
SCHEMBL13476431 0.71 SLC6A2 (0.59) SLC6A2SLC6A4SLC6A3OPRM1
Hydrochloric Acid SCHEMBL28035048 0.70 SLC6A3 (0.54) SLC6A2SLC6A4SLC6A3KMT2A
SCHEMBL14879852 0.69 TPSAB1 (0.45) KCNH2
SCHEMBL13476432 0.68 SLC6A2 (0.54) SLC6A2SLC6A4SLC6A3SIGMAR1OPRM1
SCHEMBL2280294 0.68 QDPR (0.51) DRD2
SCHEMBL6207015 0.68 SLC6A2 (0.46) SLC6A2SLC6A4SLC6A3KCNH2SLC18A3
SCHEMBL4905787 0.67 DGAT1 (0.45) HRH1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1996550-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES Novartis AG (CH) 2008-12-03 EP disclosed
WO-2007038459-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES NOVARTIS AG (CH) 2007-04-05 WO disclosed